trending Market Intelligence /marketintelligence/en/news-insights/trending/nik0xsehzcovcvvbziisyq2 content esgSubNav
In This List

Mylan, Biocon biosimilar approved in EU, Australia

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Mylan, Biocon biosimilar approved in EU, Australia

The European Commission approved Semglee, a biosimilar version of Sanofi's blockbuster drug Lantus.

Mylan NV and India-based biotechnology company Biocon Ltd. co-developed the medicine, intended for diabetes patients. The biosimilar was also approved in Australia.

The companies are also seeking approval for Semglee in U.S. and Canada.

Sanofi's Lantus generated €4.62 billion in global sales in 2017, the most in its diabetes franchise, which had combined sales of €6.40 billion the same year.